Exicure Inc (XCUR) Stock Price, Quote & News

Company Profile

Exicure, Inc. does not have significant operations. Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 847 673 1700

Website: www.exicuretx.com

Address:

400 Seaport Court, Suite 102, Redwood City, United States

Wooyongjin Dec. 14 at 1:45 AM

$XCUR The parent company is in crisis, is there any problem?

0 · Reply

RapidFury Dec. 13 at 6:28 PM

ARBB broke out on Friday, Setting itself up for a parabolic move up. Keep it on that watchlist. They are sending all these micro float cap tickers on insane rallies recently. Would not even be shocked if they send ARBB for 500% next. Only 640k shares outstanding to buy 💎 Sprit runs on $WBUY $NCPL $YXT $XCUR ..

0 · Reply

BLD33 Dec. 12 at 4:19 PM

$XCUR real value , over 10

0 · Reply

S1mpleGOAT Dec. 12 at 12:27 PM

$XCUR

0 · Reply

wallstreetjets Dec. 12 at 5:10 AM

$CLIK news coming !! Post acquisitions! Some updates here would be 💥 $XCUR $TGL $TWG this nano float! Hong Kong 🇭🇰 Perfect storm 🌪️

1 · Reply

Juve82a Dec. 11 at 10:13 PM

$XCUR 🤣💩

0 · Reply

dixiebull Dec. 11 at 9:20 PM

$XCUR thanks to @ProtraderJS we were on alert for this play, some of us got above 5.05

0 · Reply

dixiebull Dec. 11 at 9:04 PM

wanted $XCUR to hold 6

0 · Reply

Stockyoptions Dec. 11 at 8:50 PM

$XCUR 👀👁️

0 · Reply

dixiebull Dec. 11 at 8:39 PM

$XCUR keep watching

1 · Reply

Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial

Dec 8, 2025, 4:30 PM EST - 5 days ago

Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

Nov 7, 2025, 4:00 PM EST - 5 weeks ago

Exicure, Inc. Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 9:00 AM EST - 5 weeks ago

New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

Oct 22, 2025, 4:15 PM EDT - 7 weeks ago

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 6, 2025, 7:00 AM EDT - 2 months ago

Exicure Highlights Recent Achievements and Near-term Strategic Priorities

Aug 8, 2025, 4:19 PM EDT - 4 months ago

Exicure Posts Wider Loss in Fiscal Q2

Aug 8, 2025, 4:01 PM EDT - 4 months ago

Exicure, Inc. Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 4:37 PM EDT - 4 months ago

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

Aug 1, 2025, 4:01 PM EDT - 4 months ago

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Jun 27, 2025, 4:01 PM EDT - 6 months ago

Exicure, Inc. Reports First Quarter 2025 Financial Results

May 28, 2025, 4:58 PM EDT - 7 months ago

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

May 5, 2025, 8:00 AM EDT - 7 months ago

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Apr 14, 2025, 6:11 PM EDT - 8 months ago

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Apr 11, 2025, 7:42 PM EDT - 8 months ago

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Mar 18, 2025, 4:01 PM EDT - 9 months ago

Exicure, Inc. Reports Full Year 2024 Financial Results

Mar 13, 2025, 4:08 PM EDT - 9 months ago

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

Jan 23, 2025, 12:17 AM EST - 11 months ago

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Jan 22, 2025, 4:01 PM EST - 11 months ago

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Dec 26, 2024, 8:08 PM EST - 1 year ago

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

Dec 21, 2024, 1:48 PM EST - 1 year ago

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Dec 20, 2024, 4:42 PM EST - 1 year ago

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Nov 14, 2024, 4:01 PM EST - 1 year ago

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Sep 18, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Aug 26, 2024, 9:08 AM EDT - 1 year ago

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Aug 19, 2024, 10:31 AM EDT - 1 year ago

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

Aug 15, 2024, 10:31 AM EDT - 1 year ago

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 4:27 PM EDT - 1 year ago

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Jun 17, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports First Quarter 2024 Financial Results

Jun 6, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports Full Year 2023 Financial Results

May 23, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

May 16, 2024, 4:08 PM EDT - 1 year ago

Exicure, Inc. Reports Third Quarter 2023 Financial Results

Apr 22, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

Feb 5, 2024, 4:01 PM EST - 2 years ago

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Aug 23, 2023, 9:48 AM EDT - 2 years ago

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Aug 11, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 14, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 26, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

May 4, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

Mar 27, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

Feb 24, 2023, 5:10 PM EST - 3 years ago

Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors

Dec 14, 2022, 5:00 AM EST - 3 years ago

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

Nov 14, 2022, 4:01 PM EST - 3 years ago

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 26, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives

Sep 1, 2022, 7:00 AM EDT - 3 years ago

Exicure Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

Aug 15, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress

Jul 20, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jun 29, 2022, 12:00 PM EDT - 3 years ago

Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split

Wooyongjin Dec. 14 at 1:45 AM

$XCUR The parent company is in crisis, is there any problem?

0 · Reply

RapidFury Dec. 13 at 6:28 PM

0 · Reply

BLD33 Dec. 12 at 4:19 PM

$XCUR real value , over 10

0 · Reply

S1mpleGOAT Dec. 12 at 12:27 PM

$XCUR

0 · Reply

wallstreetjets Dec. 12 at 5:10 AM

$CLIK news coming !! Post acquisitions! Some updates here would be 💥 $XCUR $TGL $TWG this nano float! Hong Kong 🇭🇰 Perfect storm 🌪️

1 · Reply

Juve82a Dec. 11 at 10:13 PM

$XCUR 🤣💩

0 · Reply

dixiebull Dec. 11 at 9:20 PM

$XCUR thanks to @ProtraderJS we were on alert for this play, some of us got above 5.05

0 · Reply

dixiebull Dec. 11 at 9:04 PM

wanted $XCUR to hold 6

0 · Reply

Stockyoptions Dec. 11 at 8:50 PM

$XCUR 👀👁️

0 · Reply

dixiebull Dec. 11 at 8:39 PM

$XCUR keep watching

1 · Reply

BLD33 Dec. 11 at 8:34 PM

$XCUR Breaking

0 · Reply

BearishAlgo Dec. 11 at 8:31 PM

$XCUR watching for a short

0 · Reply

dixiebull Dec. 11 at 8:26 PM

$XCUR baby!

0 · Reply

dixiebull Dec. 11 at 8:20 PM

$XCUR hmm

0 · Reply

wallstreetjets Dec. 11 at 7:10 PM

$CLIK news coming !! Post acquisitions! Some updates here would be 💥 $XCUR $TGL $TWG this nano float! Hong Kong 🇭🇰 Perfect storm 🌪️

1 · Reply

Juve82a Dec. 11 at 4:59 PM

$XCUR wow they had 100 shares available today to borrow and look at the fee

0 · Reply

triderifusing Dec. 11 at 4:07 PM

$XCUR 247% fee https://www.iborrowdesk.com/report/XCUR

0 · Reply

Juve82a Dec. 11 at 11:31 AM

$XCUR come on you pos

0 · Reply

triderifusing Dec. 11 at 7:46 AM

$XCUR 7 coming

0 · Reply

Rvazstocksfl Dec. 11 at 7:23 AM

$XCUR under 5 coming

0 · Reply

GhostOfFrankie4Fingers Dec. 11 at 12:13 AM

$XCUR Brutal stock to baghold.

1 · Reply

Rvazstocksfl Dec. 10 at 10:56 PM

$XCUR congratulations. 60% profits?

2 · Reply

Market Cap	40.47M
Revenue (ttm)	500,000.00
Net Income (ttm)	-9.70M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,940.00%
Debt to Equity Ratio	0.00

Volume	224,200
Avg Vol	832,050
Day's Range	N/A - N/A
Shares Out	6.37M
Stochastic %K	35%
Beta	4.08
Analysts	Strong Buy
Price Target	$2.00